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Stem cells for kidney repair:  
useful tool for acute renal failure?
Takashi Yokoo1, Tetsuya Kawamura1 and Eiji Kobayashi2
Several cell types isolated from adult tissues have been reported to 
differentiate into mature kidney cells that may participate in renal 
repair after systemic administration. Chen et al. report that local 
mesenchymal stem cells derived from adult mouse kidneys are another 
source of cells with similar properties. Although these cells have the 
potential to differentiate into endothelial-lineage cell types, their 
therapeutic benefit to the ischemic kidney is mainly via the production 
of renoprotective factors.
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Acute renal failure (ARF) causes injury 
mainly to renal tubular epithelial cells. Over 
time, the injured tubules regenerate via cell 
proliferation, although the source of the 
cells that repopulate the injured nephron 
is not clear. Tissue regeneration may result 
from the proliferation of surviving dedif-
ferentiated cells, from renal stem cells that 
reside inside the kidney and migrate to the 
site of regeneration, or from bone marrow 
cells that gain access to the injured epithe-
lium and differentiate into mature cells.1 
It is now thought that most solid organs 
possess both endogenous and exogenous 
stem cells. After tissue injury, intrinsic tis-
sue stem cells replace damaged tissue as a 
first line of defense. If the pool of endog-
enous stem cells is exhausted, exogenous 
circulating stem cells are signaled to replen-
ish the pool and participate in tissue repair 
as a backup rescue system.2 In nephrology, 
several types of renal stem cells that are 
able to differentiate into tubular cells have 
been isolated from both adult kidney and 
bone marrow by techniques that are cur-
rently used to harvest stem cells from other 
organs, such as the heart and vessels.
The discovery of Y chromosome-positive 
tubular cells in kidney transplants from 
female donors after they recover from 
acute kidney failure3 has given rise to 
the hypothesis that some renal stem cells 
are resident in and are mobilized from 
the bone marrow. A number of studies 
have reported on the transplantation of 
bone marrow cells marked with LacZ, 
enhanced green fluorescent protein, or a 
genetic marker (Y chromosome) and their 
subsequent detection after the induction 
of renal damage. Renal tubular cells bear-
ing these markers have been detected, 
indicating that some fraction of the trans-
planted bone marrow cells (bulk fraction, 
hemato poietic stem cells, and/or mesen-
chymal stem cells (MSCs)) contributed to 
renal repair following experimental ARF. 
However, Duffield et al.4 recently demon-
strated that all the systems used in earlier 
studies to detect these markers, although 
well established, were capable of producing 
false-positive results, which could overesti-
mate the regenerative contribution of bone 
marrow-derived cells to renal repair.
Several attempts have been made to 
isolate tissue stem cells from adult kid-
ney. The techniques used have relied on 
the detection of cell-surface markers 
expressed universally in tissue stem cells, 
including CD133, Nestin, and CD24; 
microdissection and limiting-dilution 
methods; and the detection of side-pop-
ulation cells using Hoechst 33342 dye 
and fluorescence-activated cell sorting. In 
addition, on the basis of the assumption 
that tissue stem cells cycle very slowly and 
differentiate only as demanded by tissue 
turnover, slow-cycling cells tagged with 
the DNA marker bromodeoxyuridine 
are identified as stem cells. All these stem 
cells resident in tissue have the potential 
to differentiate into tubular cells and pro-
liferate following tissue injury. Plotkin 
and Goligorsky have previously reported 
that the adult mouse kidney contains 
MSCs with embryonic stromal charac-
teristics.5 Chen et al.6 (this issue) now 
report that local MSCs have the potential 
to differentiate into endothelial lineage 
and participate in renal repair through 
a local paracrine effect, mainly the pro-
duction of vascular endothelial growth 
factor to prevent microvascular dropout. 
Although it has been reported previously 
that MSCs derived from bone marrow 
can differentiate into endothelial cells 
and that their systemic administration 
can protect against ischemic renal fail-
ure through differentiation-independent 
mechanisms, Chen et al.6 shed light on 
the unique characteristics of local MSCs 
as useful vehicles for cell therapy to pro-
duce tissue regeneration after ARF. One 
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issue that remains unresolved is whether 
local MSCs are physiologically functional 
in the adult kidney, because Chen et al.6 
used cloned MSCs that were expanded 
in vitro as a surrogate for the behavior 
of resident cells. The number of local 
MSCs in the adult kidney and whether 
this population is sufficient to maintain 
normal turnover and recovery from ARF 
remain to be determined. In addition, it 
is not clear to what extent the behavior of 
expanded cloned cells reflects the physi-
ological condition. It has been reported 
that resident tissue stem cells constitute 
only a small percentage of the total cel-
lularity of an organ.7 This suggests that 
tissue-specific stem cells are less impor-
tant under normal conditions, that their 
numbers are not sufficient for therapeutic 
regeneration after tissue injury, and that 
they must be either expanded in vivo or 
supplied on demand from the circulation. 
In this regard, MSCs are well characterized 
and can be expanded in vitro without loss 
of pluripotency. Thus, local MSCs may be 
a useful vehicle for cell therapy for tissue 
regeneration after ARF.
There are many reports of tissue stem 
cells, including local MSCs, that are able 
to differentiate into mature renal cells and 
participate in renal repair. However, the 
question remains of whether these cells are 
of the same or different populations. It has 
been suggested that, in the kidney, stem cell 
niches are located in the interstitium of the 
cortex, as well as the papilla and tubules. 
According to a previous report, it is likely 
that the niche for local MSCs in the adult 
kidney may be perivascular in nature.8 
This suggests there are several sources 
of renal stem cells in the adult kidney 
but does not exclude the possibility that 
stem cells can be mobilized and localized 
to anywhere in the adult kidney. If so, the 
same type of stem cell may be identified 
as a different population. Recent evidence 
suggests that liver progenitor cells, called 
oval cells, which transdifferentiate into 
hepatocytes or biliary epithelial cells, may 
originate not only from the point where 
the terminal bile ducts meet the periportal 
hepatocytes, but also from the bone mar-
row.9 It is equally likely that the source of 
other stem cells, including those in the 
kidney, is not restricted to one location 
and that stem cells may be supplied from 
different sources depending on the sever-
ity, location, and duration of damage.
Another question that is then raised 
is which cell is best for cell therapy of 
ARF. The discovery of tissue stem cells 
has fueled intense research interest in 
the field of regenerative medicine in the 
kidney, which holds enormous therapeu-
tic potential. Despite the optimism, debate 
continues regarding the feasibility of such 
therapy. Many papers have been published 
reporting the discovery of renal stem cell 
populations in the kidney and bone mar-
row, and the therapeutic potential of their 
administration in ARF. These findings 
have brought the possibility of organ 
regeneration using somatic stem cells a 
step closer to realization (Figure 1). It was 
recently reported that pluripotent embry-
onic stem (ES)-like cells, termed iPS cells, 
could be produced from cultured somatic 
cells by retroviral transfer with Ocr3/4, 
Sox2, and Klf4, transcription factors asso-
ciated with pluripotency.10 Because human 
iPS cells can be induced from adult skin 
fibroblasts with considerably less stress 
than that associated with renal biopsy and 
bone marrow aspiration, these cells may 
be another candidate for the cell therapy 
of ARF. It appears that many research-
ers have started to examine the feasibil-
ity of using iPS cells in the treatment of 
renal disease. Consequently, we must now 
address whether regenerative medicine is 
truly useful and practical in the treatment 
of clinical ARF and, if so, which cell popu-
lation is best suited to this purpose.
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Uremic lung: new insights  
into a forgotten condition
Paul J. Scheel1, Manchang Liu1 and Hamid Rabb1
The high mortality rate of acute kidney injury (AKI) despite advances in 
dialysis led to a renewed appreciation of the impact of AKI on distant 
organ dysfunction. Mechanistic studies demonstrated that AKI induces 
increased lung vascular permeability, soluble and cellular inflammation, 
and dysregulated salt and water channels. AKI also affects the brain, heart, 
liver, bone marrow, and gastrointestinal tract. Klein et al. now demonstrate 
that interleukin-6 is a direct mediator of AKI-induced lung changes.
Kidney International (2008) 74, 849–851. doi:10.1038/ki.2008.390
The modern era of the study of the patho-
physiology of acute renal failure (currently 
referred to as acute kidney injury, AKI) 
began with the publication of the land-
mark observations of Bywaters and Beall1 
in the early 1940s with their description 
of the physiologic changes observed in 
soldiers suffering from AKI attributed to 
crush injury. Unfortunately, only support-
ive therapy was available, and the mortality 
in this population was greater than 90%. 
In the 1950s it was identified that the lung 
can also be injured during AKI, with these 
patients manifesting abnormal chest X-rays 
postulated to be secondary to “increased 
permeability of congested pulmonary 
capillaries.”2 These lung changes were also 
identified in chronic kidney disease, and 
dubbed ‘uremic lung.’ With the introduc-
tion of dialysis in the 1950s, the mortality 
rates associated with AKI decreased to 
50%–60%. With fluid removal by dialysis, 
many believed that ‘uremic lung’ was no 
longer a real entity, that the lung changes 
observed during kidney dysfunction were 
entirely due to increased effective blood 
volume, and that dialysis was the answer 
for patients with AKI. Unfortunately, over 
the past 50 years there has been minimal 
improvement in this high mortality rate 
despite improvements in dialysis technol-
ogy and advances in supportive care.
AKI still remains a common condition 
in hospitalized patients, especially those 
in an intensive care unit (ICU) setting. A 
multicenter, multinational study found 
that 6% of ICU patients had severe enough 
AKI to require renal replacement therapy.3 
While newer studies have confirmed the 
high rates of renal injury in an ICU set-
ting, these have also alerted the renal com-
munity to previously unforeseen effects of 
mild to moderate kidney injury — those of 
increased mortality with mild to moder-
ate elevations in serum creatinine. Patients 
with a 25% increase in serum creatinine 
secondary to radiocontrast injection had 
a fivefold increase in hospital mortal-
ity.4 In an analysis of hospital records of 
19,982 adult patients, a more than 0.5 
mg/dl increase in serum creatinine was 
associated with a 6.5-fold increase in the 
odds of death.5 Though most believed that 
the high mortality rate was from patients 
dying ‘with renal disease,’ increasing data 
now support that patients are dying ‘from 
renal disease.’
How does one explain the relationship 
between AKI and escalating mortality? Is 
AKI merely an indicator of severe organ 
injury, and dialysis only changing the 
cause of death rather than incidence and 
timing? Does AKI directly, either through 
direct kidney injury or inability to clear 
toxic substances, lead to distant organ dys-
function that in turn predisposes to death? 
To evaluate whether AKI directly effects 
distant organ function, and whether the 
entity called ‘uremic lung’ is indeed real, 
mechanistic studies with new tools have 
been performed in rodents during AKI. 
AKI increased pulmonary vascular albu-
min permeability, erythrocyte sludging 
in lung capillaries, and interstitial edema, 
even when animals did not acutely gain 
total body fluids.6 Furthermore, interven-
ing by dampening systemic macrophage 
function partially attenuated lung changes 
after AKI. The increased lung interstitial 
edema was associated with dysregulated 
lung salt and water transporters, notably 
ENaC, Na, K-ATPase, and aquaporin-5.7 
The lung changes after AKI were found 
to start early and could be attenuated with 
α-melanocyte-stimulating hormone, a 
broad anti-inflammatory agent.8 Comorbid 
conditions such as sickle-cell disease accen-
tuated AKI effects on the lung.9 Detailed 
genomic analysis followed by polymerase 
chain reaction and protein studies led to the 
prediction that multiple pathways, includ-
ing interleukin-6 (IL-6), IL-10, endothelin, 
and serum amyloid 3, could mediate AKI-
induced lung dysfunction.10,11 AKI leads 
to abnormalities in many other organs 
besides the lung (Figure 1). AKI has been 
reported to increase cardiac apoptosis and 
production of IL-1 and tumor necrosis fac-
tor.12 Given that severe AKI is well known 
to cause uremic encephalopathy, a classic 
indication to initiate dialysis, the effects of 
AKI on the brain have been studied exper-
imentally. In mice, AKI led to increased 
expression of glial fibrillary acidic protein 
(a marker of inflammation) in astrocytes in 
the cortex and corpus callosum, activation 
of microglia (brain macrophages), increased 
vascular permeability to blood albumin, 
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